Lates News

Sanofi's innovative drug Caplacizumab has been approved by the National Medical Products Administration for marketing in adult and adolescent patients aged 12 and older weighing at least 40 kg with acquired thrombotic thrombocytopenic purpura, for use in combination with plasma exchange and immunosuppressive therapy. Coinciding with the first day of the Import Expo, Sanofi also showcased this drug at the conference. Sherwin Shih, President of Sanofi China, said, "Thanks to the support of the national priority review for clinical urgently needed rare disease treatment drugs, Caplacizumab has entered the 'fast lane' of review in China, with the time from submitting the application to approval taking only 6 months." (Yicai)